Joined the holders in CBF this morning. Looks like a recovery going on here and I here whispers well speculation of new contract wins. The company seems to be moving away from DNA and focusing on protein and virus production and they seem to be far more focussed.

The company have restructured their sales and marketing team and appear to be more aggresive in their actions.

Fixed and variable costs have also been attacked and the company is working from a lower cost base. The companys order book is higher than it as been for a while and I beleive quarterly profit will be achieved.

Chart also looks strong and shows a break up.

Pointers To Recovery.

From last results 11th Jan.

Sales improvement in the second half of the financial year due to switch
from DNA to proteins and virus.



Restructuring of sales and marketing to address US market.



Restructuring of the Oxford and Keele facilities.



Broadening of customer base - 12 new customers in 2004.



The 4.8m Oxford Facility completed on time and to budget.



Contracted business for financial year 2005 stands at 2.7m.



Financial:


Revenue: H2 2004 up 30% to 2.0m compared with H1 2004 1.5m
FY 2004 down 42% to 3.5m (FY 2003: 6.0m)

Gross margin: H2 2004 49% compared with H1 2004 39%
FY 2004 45% (FY 2003: 57%)

Loss before tax: H2 2004 reduced by 17% to 1.03m compared with H1 2004 1.24m
FY 2004 2.27m (FY 2003: 0.82m profit)

Cash at bank: Sept 2004 3.2m compared with Mar 2004 3.8m (FY 2003: 7.3m)

Loss per share: FY 2004 12.3p (FY 2003: 6.9p earnings)

Director Speak

Commenting on the results, Peter Fothergill, Executive Chairman said:

'Our second half improvement and the current position of our order book are
significant achievements. Management moved rapidly during the year to focus
sales and marketing in the US and from DNA to virus and protein production. This
was no mean feat and we are cautiously optimistic for the future.'

Company Outlook Statement.

Management is actively seeking to broaden the customerbase particularly in the US biotechnology clusters and is examining ways toexpand the service offering including later stage manufacture and there by developing longer-term relationships which can reduce the impact of the high levels of clinical trials failure. These initiatives are already beginning to gain traction with contracted business currently 2.7 million for the financial year 2005 ('2005'), with 52% from North America. If this improvement continues Cobra will recover value for its shareholders.

Fundies.

Presently loss making but looks like the corner has been turned. Awaiting next trading update/results.

Beta.

Fairly High.

Conclusion

Highly Speculative, but the rewards if recovery does take place could be very rewarding.



cheers GF.

Thanks for that Bankone, a really positive statement and seems to bode well for the future even with EK in this.
DB66

Evils long on it DB. Strange but have a look at the trades after the AGM?????????????????????????????????????????., ie after the 11.15 am announcement look to be all sells . Have I missed some news whilst on holiday or where investors expecting more from the company ?????????????.

cheers GF.

Cobra Bio-Manufacturing says H1 positive, sales up 50 pct vs previous 6 mths
AFX


LONDON (AFX) - Cobra Bio-Manufacturing PLC said it has had a 'positive' six months and is currently trading well.

Revenue for the first half of 2005 is up 50 pct from the previous six months to 3.0 mln stg and the opening contracted business for the second half of the financial year is 2.8 mln.

'Our change of focus from the smaller DNA market to the manufacture of virus and the much larger market for proteins has been very effective; protein contracts now account for 48 pct and virus contracts for 33 pct of our contracted business for financial year 2005,' the company said.

'Additionally focusing our sales efforts on the publicly listed biotechnology companies in North America is also proving to be very successful and this market now represents 75 pct of the current year's order book, including part of a long term contract worth in excess of 3.6 mln usd.'

The company added: 'The overall business environment continues to improve, and the company is competing well as demonstrated by the number of important contracts announced since the beginning of the calendar year.'

bam

I think cobras held up quite well considering the amount of sells in recent
days.
http://biz.yahoo.com/prnews/050407/to286.html?.v=2

Goldfinger are you sure Evil hasn`t changed his mind? i`m sitting on a small profit and don`t want to lose like i did in MMG. Evil`s getting his arse kicked with SEO so i am wondering if his turning his attention to CBF.
db66

DB he closed down Stanelco last week. Hes certainly long of Cobra and not the other way round.

Nice rise in these aswell today. Good day all round.

cheers GF. PS PM for you.

Well at least this was positive today.

cheers GF.

Holding steady again at the moment,but 150,000 sell has just
gone through and for Cobra that is a big amount!
DB66

RNS Number:8185L
Cobra Bio-Manufacturing PLC
04 May 2005


For Immediate Release 4 May 2005


Cobra Biomanufacturing and Synco BioPartners form alliance to manufacture
plasmid DNA for Phase III trials and commercial supply


Keele, UK, 4 May 2005 - Cobra Biomanufacturing Plc (AIM:CBF.L), the
international manufacturer of biopharmaceuticals and Amsterdam Netherlands,
Synco BioPartners, a leading, contract manufacturing organization, announce they
have formed an alliance to manufacture plasmid DNA for Phase III trials and
commercial supply.

Under the terms of the agreement, Synco has acquired the license to Cobra's
intellectual property rights in the pDNA manufacturing process. This will enable
Synco to manufacture pDNA for both Phase III studies and for commercial supply.
Cobra will continue to offer preclinical, Phase I and Phase II pDNA manufacture.

Synco and Cobra have also agreed to collaborate in the marketing of their pDNA
manufacturing services and to collaborate in providing a first class, integrated
service to potential customers.

Thatcher, Chief Executive, Cobra Biomanufacturing said: "Cobra is proud to
form this important alliance with Synco BioPartners, "Synco is a leading
manufacturer with a licensed facility and an impressive track record in the
production of large-scale recombinant biopharmaceuticals and vaccines for
clinical trials and market supply. Synco has immense manufacturing strengths,
which truly complement Cobra's capabilities in development and IP, making them
an ideal partner."

Pierre Warffemius, CEO of Synco BioPartners B.V. added: " This agreement
leverages our position as a leading CMO in the biopharmaceutical market. We look
forward to a very productive collaboration with Cobra, who are a recognized
leader in the plasmid DNA market and has impressive IP. I believe there are
great synergies between their expertise in pDNA and our specialist, large-scale
manufacturing capabilities and I look forward to offering customers a first
class service".

RNS Number:6446M
Cobra Bio-Manufacturing PLC
24 May 2005

For Immediate Release 24 May 2005

COBRA BIOMANUFACTURING PLC

COBRA SIGNS AGREEMENT WITH INTROGEN THERAPEUTICS FOR MANUFACTURING SERVICES

Keele, UK: Cobra Biomanufacturing plc (AIM: CBF), the international manufacturer
of biopharmaceuticals, today announces an agreement with Introgen Therapeutics,
Inc. (NASDAQ: INGN) for production services.

Cobra will use its expertise in the development of DNA manufacturing strategies
and analytical development to provide GMP manufacturing services for one of
Introgen's clinical stage programs. Financial terms of the agreement were not
disclosed.

David Thatcher, Chief Executive of Cobra, said: "We very much look forward to
helping to provide the manufacturing needs of another US customer. Cobra is
delighted to have the opportunity to apply its experience to one of Introgen's
innovative products now in development. This agreement potentially covers
production of multiple batches of product over the next few years and can add
significant value to Cobra's income stream "

Dr. Peter Clarke, Introgen's Vice President for Production and Technical
Processes, added: "We look forward to working with Cobra as we expand our
programs to include new areas of therapeutic DNA product development. We
believe international relationships can enhance our corporate mission and expand
product development opportunities."


Notes for Editors

About Cobra Biomanufacturing

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products. Cobra was
the first company to develop GMP (Good Manufacturing Practice) standard DNA
manufacture in Europe, with specific expertise in DNA medicines. A range of
unique, patented technologies, underpins this revenue generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising #7 million and raised a further #5.25 million in May 2003
in order to further expand capacity in Oxford UK.

About Introgen Therapeutics, Inc.

Introgen Therapeutics, Inc. is a leading developer of biopharmaceutical products
designed to induce therapeutic protein expression using non-integrating gene
agents for the treatment of cancer and other diseases. Introgen maintains
integrated research, development, manufacturing, clinical and regulatory
departments and operates a commercial-scale, CGMP manufacturing facility.

This information is provided by RNS
The company news service from the London Stock Exchange

Haven't followed Cobra really so not up with its history. But I am wondering why its been falling and continues to fall on apparently good news? Was more expected?

Cheers, Madison

After the recent dip in SP a welcome rise today.
On the 6th June Fidelity International notified the company stating they owned 701,900 share , 3.60 per cent.Given also that Evil holds a long position in Cobra i am hoping for a rise back to the 70p level that we recently saw.
DB66

A nice rise up today on the news that the interim results for six months ended 31st March will be announced on Thursday 30th June and not Tuesday 5th July as previously stated.

DB66

Huge drop today to 47p...looks like more downside on the way.

Time to BUY!!! added another 14K worth today.

Looks like some expansion may be going on at Cobra, they are advertising for at least eleven new staff at Oxford and Keele in the November 18th issue of New Scientist. Note use of plural/singular for the production scientist posts.

OXFORD:
Team Leader Microbiology,
Microbiologist,
QA Officer,
QC Analytical Scientist,
Team Leader Upstream Processing,
Team Leader Downstream Processing,
Senior Production Scientist(s),
Production Scientists(s).

KEELE FACILITY:
QC Team Leader,
GMP Production Supervisor for Microbial fermentation,
Senior Research Molecular Biologist.
copied from the other side

The big question is just how big a PROFIT we have made this year.
dyor

Little interest here, but the trend is down since earlier 2007 - and the GSK issue is bad news. although I suspect the sp reaction is overdone as they weren't banking on this work....it's not like your No1 customer has left suddenly.
Don't know what the trend is saying, though any ideas?
Anyone?

A year later and no comments!

Grief - Look at the SP fall.
Er, just what's up?

Ah Funding issues. . . . . well, we can expect a huge dilution at about 10p-ish I'm guessing.....oh deary....

Does the UK produce any good Executives?


EDIT - read latest RNS - it seems the Dixons have (with others) bought shares at 5p recently increasing their % but by arrangement they don't have to mount a full takeover.
This is a BAD scenario, IMHO.......did any other investors miss-out. Cheated, shafted come to mind....Ouch!
All IMHO - DYOR.

The directors appear to have benefitted from this emergency placing; why not a full rights issue to give all shareholders a chance.

Some qusetions need to be asked at the EGM